News & Updates

Rapid point-of-care testing enables timely and targeted RTI treatment

According to the 2021 Global Burden of Disease (GBD) study, COVID-19 and lower respiratory tract infections (LRTIs) ranked as the 1st and 5th leading causes of global disease burden across all age groups and genders.

Rapid point-of-care tests (POCTs) enable timely diagnosis, particularly in vulnerable populations at higher risk of severe illness, complications, and hospitalization. 

VTE prevention and treatment: Role of fondaparinux in hospitalized patients

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is highly prevalent among hospitalized patients, potentially fatal, yet preventable. In an interview with MIMS Doctor, Dr Andy Sing-Ong Tang, Clinical Haematologist of the Sarawak General Hospital, Kuching, Sarawak, Malaysia, discussed the role of fondaparinux in prevention and treatment of VTE among hospitalized patients, with a particular focus on obese and Muslim patients.

Vaccination crucial to integrated dengue prevention and control in SEA

Southeast Asia (SEA) is one of the hotspots for dengue infections, with Indonesia and Thailand among the highly endemic countries. At a Takeda-sponsored symposium held during the 2nd APIC-ADVA Asia Pacific Summit on Infectious Diseases and Immunization in Singapore, experts focused on vaccination as an integral component of a holistic dengue prevention and control strategy in SEA.

*The editorial below is supported by Takeda Pharmaceuticals International AG Singapore Branch and is intended solely for informational purposes. Takeda has not influenced or contributed to the editorial content. While Takeda has provided financial support for the editorial, Takeda shall not be held responsible or liable for any errors, omissions, or inaccuracies in such information.

Role of CGRP in acute migraine treatment and prevention: Evolving strategies and regional insights

This article highlights key insights from the Asia Migraine Healers Academy 2025, a Pfizer-organized event in Kuala Lumpur, Malaysia, where renowned experts Professor Andrew Charles (US) and Dr Mianwang He (China) discussed advancements in migraine management.

New adjuvanted shingles vaccine safely yields long-term high efficacy in high-risk groups

An expert panel discusses shingles, its disabling impact on high-risk persons and the safety and efficacy of a newly available adjuvanted shingles vaccine in a launch.

Combination of hyaluronic acid matrix, undenatured type II collagen and Boswellia serrata gum extract for superior, rapid and long-term pain relief in osteoarthritis patients

Two specialists discuss case studies on osteoarthritis specifically related to the proven long-term pain relief properties of a combination of hyaluronic acid matrix, undenatured type II collagen and Boswellia serrata gum extract.

Silent but Serious: A Comprehensive Look at IgA Nephropathy and C3 Glomerulopathy in Glomerulonephritis

Glomerulonephritis (GN) is a group of immune-mediated disorders that result in glomerular injury. It can arise from both primary renal diseases, such as immunoglobulin A nephropathy (cardiovascular complications) and C3 glomerulopathy (C3G), or secondary conditions like lupus nephritis (LN). IgAN has shown an increasing trend in Malaysia, with prevalence of biopsy proven IgAN rising from19.6% (2005-2009) to 29.5% (2020), based on recent findings. In contrast, C3G is an ultra-rare and severe form of GN. However, there is currently no available data on the incidence or prevalence of GN in Malaysia. Without timely intervention, GN can lead to the progression of chronic kidney disease (CKD) or end-stage renal disease (ESRD), often accompanied by cardiovascular complications. Early diagnosis and personalised management are crucial for slowing disease progression and improving patient outcomes.

A holistic approach to atopic dermatitis: Skin barriers, core therapies and adjunctive strategies

During the first Breakfast Symposium at the 33rd Singapore Pharmacy Congress on 5 October 2024, Dr Lucinda Tan emphasised the importance of maintaining a healthy skin barrier in patients with atopic dermatitis (AD) and provided an overview of the available management and treatment options.

Revolutionising hyperpigmentation treatment with Melasyl

At the recent 26th Regional Conference of Dermatology, a panel of experts in dermatology discussed the treatment of pigmentation and its impact on quality of life. Subsequently the symposium highlighted on an innovative new molecule called Melasyl. The panel, chaired by Dr Peter Ch’ng, consultant dermatologist and internal medicine specialist, featured Dr Angeline Yong, consultant dermatologist and dermatological surgeon, Dr Angeline Tay, from L’Oréal Research and Innovation, Singapore, and Professor Goh Chee Leok, senior consultant dermatologist, National Skin Centre, Singapore

Luspatercept transforming the management of β-thalassaemia

β-thalassaemia, an inherited haemoglobin disorder, affects approximately 1.5 percent of the global population, with 60,000 symptomatic individuals born annually, predominantly in low- and middle-income countries. [Orphanet J Rare Dis 2010;5:11]